Literature DB >> 8058105

Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors.

C A Rizzi1, A Sagrada, A Schiavone, P Schiantarelli, R Cesana, G B Schiavi, H Ladinsky, A Donetti.   

Abstract

We have investigated the in vivo motor stimulating and gastroprokinetic properties of the azabicycloalkyl benzimidazolone derivative BIMU 1 (3-ethyl-2,3-dihydro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-oxo-1H- benzimidazole-1-carboxamide hydrochloride) and its binding profile at 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptors, in an attempt to assess the serotonergic mechanism underlying its prokinetic action. BIMU 1 dose-dependently (0.01-0.3 mg/kg i.v.) increased the motility of a denervated pouch of canine stomach. This excitatory action was sensitive to muscarinic blockade. A similar stimulatory effect was exerted by the benzamidic prokinetic agent cisapride (0.03-0.3 mg/kg i.v.) but not by the 5-HT3 receptor antagonist ondansetron (up to 1 mg/kg i.v.). The significance for propulsive efficacy of the motor stimulating activity of BIMU 1 was evaluated in a model of gastric emptying of liquids in the conscious dog. The emptying rate of a non-caloric liquid meal instilled through a gastric fistula was accelerated by both BIMU 1 (0.01-1 mg/kg i.v. and 0.1-3 mg/kg p.o.) and cisapride (0.03-1 mg/kg i.v. and 0.3-10 mg/kg p.o.). Ondansetron (1 mg/kg i.v.) did not show any effect. The activity of the 5-HT4 receptor antagonist DAU 6285 was evaluated in the gastric emptying model per se and in interaction experiments on the accelerating action of BIMU 1 (0.3 mg/kg i.v.).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058105     DOI: 10.1007/bf00170878

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  41 in total

1.  AS-4370, a new gastrokinetic agent, enhances upper gastrointestinal motor activity in conscious dogs.

Authors:  N Yoshida; T Ito; T Karasawa; Z Itoh
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

2.  DAU 6285: a novel antagonist at the putative 5-HT4 receptor.

Authors:  A Schiavone; E Giraldo; L Giudici; M Turconi; A Sagrada
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

3.  Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs.

Authors:  G W Gullikson; R F Loeffler; M A Viriña
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

4.  Effects of 5-hydroxytryptamine 3 receptor antagonists on gastrointestinal motor activity in conscious dogs.

Authors:  N Yoshida; A Mizumoto; Y Iwanaga; Z Itoh
Journal:  J Pharmacol Exp Ther       Date:  1991-01       Impact factor: 4.030

5.  The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig.

Authors:  B Costall; S J Gunning; R J Naylor; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

6.  Identification of serotonin 5-HT3 recognition sites by radioligand binding in NG108-15 neuroblastoma-glioma cells.

Authors:  D Hoyer; H C Neijt
Journal:  Eur J Pharmacol       Date:  1987-11-10       Impact factor: 4.432

7.  Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists.

Authors:  M Turconi; M Nicola; M G Quintero; L Maiocchi; R Micheletti; E Giraldo; A Donetti
Journal:  J Med Chem       Date:  1990-08       Impact factor: 7.446

8.  Functionalized congener approach for the design of novel muscarinic agents. Synthesis and pharmacological evaluation of N-methyl-N-[4-(1-pyrrolidinyl)-2-butynyl] amides.

Authors:  B J Bradbury; J Baumgold; K A Jacobson
Journal:  J Med Chem       Date:  1990-02       Impact factor: 7.446

9.  The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons.

Authors:  A Dumuis; M Sebben; J Bockaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

10.  Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain.

Authors:  C J Grossman; G J Kilpatrick; K T Bunce
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

View more
  5 in total

1.  Small Bowel Dysmotility.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1998-12

2.  Antagonistic properties of McNeil-A-343 at 5-HT4 and 5-HT3 receptors.

Authors:  A Sagrada; G B Schiavi; E Cereda; H Ladinsky
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

3.  5-HT4 receptor mediated stimulation of gastric emptying in rats.

Authors:  S S Hegde; A G Wong; M R Perry; P Ku; T M Moy; M Loeb; R M Eglen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-06       Impact factor: 3.000

Review 4.  Serotonin pharmacology in the gastrointestinal tract: a review.

Authors:  D T Beattie; J A M Smith
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-09       Impact factor: 3.000

5.  The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors.

Authors:  A Lucchelli; M G Santagostino-Barbone; A Barbieri; S M Candura; M Tonini
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.